Chinese company completes acquisition of US firm providing immunotherapy for prostate cancer – Xinhua
|
Chinese company completes acquisition of US firm providing immunotherapy for prostate cancer
Xinhua At the heart of the deal is Dendreon's lead product, Provenge, the only cellular immunotherapy approved so far by the U.S. Food and Drug Administration (FDA) for treatment of asymptomatic or minimally symptomatic metastatic castration-resistant … |
